Abstract
Objectives Patients requiring haemodialysis are at increased risk of serious illness with SARS-CoV-2 infection. To improve the understanding of transmission risks in six Scottish renal dialysis units, we utilised the rapid whole-genome sequencing data generated by the COG-UK consortium.
Methods We combined geographical, temporal and genomic sequence data from the community and hospital to estimate the probability of infection originating from within the dialysis unit, the hospital or the community using Bayesian statistical modelling and compared these results to the details of epidemiological investigations.
Results Of 671 patients, 60 (8.9%) became infected with SARS-CoV-2, of whom 16 (27%) died. Within-unit and community transmission were both evident and an instance of transmission from the wider hospital setting was also demonstrated.
Conclusions Near-real-time SARS-CoV-2 sequencing data can facilitate tailored infection prevention and control measures, which can be targeted at reducing risk in these settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. Also MRC (MC UU 1201412), UKRI/Wellcome (COG-UK), Wellcome Trust Collaborator Award (206298/Z/17/Z: ARTIC Network; TCW Wellcome Trust Award 204802/Z/16/Z.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Use of anonymised data was approved by the Local Privacy Advisory Group of NHS Greater Glasgow and Clyde Safe Haven on behalf of the West of Scotland Ethics Committee (approval GSH/20/RE/001). Surplus RNA extract was collected for sequencing with ethical approval from the NHSGGC biorepository (16/WS/0207NHS).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data sharing statement Will individual participant data be available? Yes What data in particular will be shared? Individual participant data that underlie the results reported in this article, after de-identification. Sequences and de-identified metadata is available on MRC-CLIMB through COG-UK. Sequences are also available on GISAID. What other documents will be available? Study protocol, statistical analysis, analytic code When will data be available? Immediately following publication, no end date With whom? Researchers who provide a methodologically sound proposal For what types of analysis? To achieve aims in the approved proposal By what mechanism will data be made available? Proposals should be directed to contact{at}cogconsortium.uk (Statement from COG-UK consortium: We are committed to open science, and sharing all data that we can as rapidly as possible. This includes sharing data for use by Public Health authorities internationally, to support COVID-19 response, and sharing data in such a way that the academic community can access and use the data and analysis according to FAIR data principles.)
